Skip Navigation

COVID-19 Update

Current Clinical Trials at the Johns Hopkins Comprehensive Brain Tumor Center

Phase I Study of Neoadjuvant GMCI plus Immune Checkpoint Inhibitor Combined with Standard of Care for Newly Diagnosed High-Grade Gliomas (IRB00172749)

Contact: Michaella Iacoboni (msheeh13@jhmi.edu)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To test the safety of a treatment called Gene Mediated Cytotoxic Immunotherapy (GMCI) plus the anticancer drug nivolumab, in combination with standard radiation therapy (RT) + temozolomide (TMZ).
Eligibility Criteria: Adults with a newly diagnosed brain tumor called high grade glioma

A Phase I Trial of anti-Tim-3 in combination with anti-PD-1 and SRS in Recurrent GBM (IRB00104226)

Contact: Kelly Szajna, RN, BSN (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To find out if two study drugs PDR001 and MBG453 are safe to give with stereotactic radiosurgery (SRS).
Eligibility Criteria: Adults with recurrent glioblastoma (GBM)

Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas (IRB00151324)

Contact: Amber Michalik (410-502-0756)
Principle Investigator: Dr. Chetan Bettegowda
Objective: To test any good and bad effects of the study drugs called vemurafenib and cobimetinib
Eligibility Criteria: Adults with a craniopharyngioma which has recurred (came back).

Stereotactic Radiosurgery combined with Nivolumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine (IRB00086553)

Contact: Whitney Isennock (410-955-7008) or Kelly Szajna (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To look at the safety of using stereotactic radiosurgery (SRS) and Nivolumab together to treat melanoma that has spread to the brain or spine.
Eligibility Criteria: Adults with newly identified brain OR spinal metastases

Stereotactic Radiosurgery with Nivolumab in Subjects with Chordoma (IRB00117650)

Contact: Whitney Isennock (410-955-7008) or Kelly Szajna (410-502-4081)
Principle Investigator: Dr. Lawrence Kleinberg
Objective: To look at the safety of using Nivolumab alone or Nivolumab and stereotactic radiosurgery (SRS) together to treat advanced chordomas.
Eligibility Criteria: Advanced/recurrent Chordoma in 1 or more site

Browse other clinical trials

For a complete list of open clinical trials across Johns Hopkins, visit the database at the Institute for Clinical and Translational Research. You can search by condition, researcher or doctor’s name.

  
back to top button